問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University Hospital (在職)

Division of Hematology & Oncology

Division of Urology

Division of Thoracic Medicine

Division of Urology

Digestive System Department

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy) (在職)

Division of Urology

Division of Urology

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Urology

Division of Hematology & Oncology

更新時間：2023-09-19

劉明哲LIU, MING-CHE
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

Recruiting Trial

26Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉明哲

List

46Cases

2023-09-01 - 2027-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2023-12-01 - 2026-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2024-12-16 - 2029-12-31

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2017-04-01 - 2019-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2023-09-01 - 2026-06-30

Phase III

Active
A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Subunit Inactivated Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

  • Condition/Disease

    NA

  • Test Drug

    intramuscular injection

Participate Sites
5Sites

Recruiting5Sites

2023-09-01 - 2027-12-31

Phase I

Active
A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Food Effect and Potential Efficacy of PS1 in Human

  • Condition/Disease

    PS1

  • Test Drug

    tablet

Participate Sites
1Sites

Recruiting1Sites

2023-12-01 - 2026-12-31

Phase I/II

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
3Sites

Recruiting3Sites

2023-09-29 - 2025-01-16

Phase III

A multicenter, randomized, prospective double-blind, cross-over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs)

  • Condition/Disease

    Contrast-enhanced MRI is used to assess known or suspected pathology in body sites.

  • Test Drug

    Gadoquatrane (BAY 1747846) Dotarem (Gadoteric acid)

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting1Sites

Terminated1Sites

2023-09-01 - 2023-09-01

Phase I

A phase 1 clinical trial evaluating the safety and immunogenicity of OBI-BCVax in the prevention of COVID-19 in healthy adults.

  • Condition/Disease

    Prevention of COVID-19 infection in healthy adults

  • Test Drug

    OBI-BCVax

Participate Sites
1Sites

Not yet recruiting1Sites

2019-07-01 - 2022-09-30

Phase I

A single-blinded, randomized, placebo-controlled, dose escalation, Phase 1 study to investigate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of UB-852 after a single subcutaneous administration in healthy male adults

  • Condition/Disease

    Anemia in chronic kidney disease

  • Test Drug

    UB-852

Participate Sites
1Sites

Recruiting1Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB